secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029396
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027
---------------------------------------------------------------------------

- Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.
- Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.
- Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.
- CEO Jason Hanson to resign upon appointment of successor; Board conducting search.
- Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/0000950170-24-029396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024029396/engn-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer